January 2025 in “SKIN The Journal of Cutaneous Medicine” In this analysis of the BRAVE-AA trials, a significant number of patients with severe alopecia areata treated with baricitinib reached complete or nearly complete scalp coverage (SALT score ≤10 or ≤5) over 52 weeks, particularly among those with less severe baseline characteristics.
3 citations
,
January 2025 in “International Journal of Molecular Sciences” In this study, researchers investigated EGCG's spectroscopic properties and its interaction with DPPG lipid, finding that both experimental and theoretical approaches agree on the electronic transitions and reveal an increased absorbance due to molecular interactions.
This report describes the 2024 American Academy of Dermatology Annual Meeting in San Diego, notable for attracting nearly 20,000 attendees with 339 sessions covering a wide range of dermatological topics, making it potentially the largest dermatology meeting by attendance.
22 citations
,
August 2015 in “PloS one” This study found that the binding and release of BMP-2 from kerateine biomaterials are significantly influenced by pH and salt concentration, highlighting the potential for developing improved bone repair systems.
In this phase 2 trial, STS01 1% significantly improved hair regrowth in patients with mild to moderate patchy alopecia areata compared to placebo, with a manageable skin irritation side effect profile.
